ATCC 2023 Holiday Shipping Schedule: We will be closed from December 22nd to January 1st. To ensure timely delivery, please submit orders in accordance with the following: Domestic orders no later than December 15th for shipment by December 20th 2023; International orders no later than December 12th for shipment by the first week of January 2024. We will resume our normal shipping schedule on January 2nd, 2024. Thank you for your cooperation. 

  • Quick Order
  • Careers
  • Support


Checkpoint inhibitor therapeutic antibody blocking PD-1 protein on T cell and preventing it to bind to PD-1L on cancer cell

Fight cancer with the power of the immune system


Cancer immunotherapy has emerged as an exciting new approach for cancer treatment, and immuno-oncology is one of the fastest growing fields in oncology. As compared to traditional cancer therapies that act directly on cancerous tumors, immuno-oncology therapy offers a unique approach that uses the body’s immune system to selectively target and eradicate tumor cells. These therapies also provide long-lasting memory to the immune system, enabling it to continue fighting against cancer cells even after remission.

The development of immunomodulatory drugs and biologics dictates a clear need for human cell-based models to evaluate immune activation. To answer this need, ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models.

Your Chance to Win the Latest Models for Immunotherapy Development

Want a chance to win vials of the checkpoint luciferase reporter cells or CAR-T target luciferase reporter cells? Join our innovation challenge!
Don’t delay—the submission period ends December 1, 2023.

Join the challenge

Explore our immuno-oncology products and resources

Refine by